COLOTECT is a non-invasive colorectal cancer (CRC) self-sampling test that can 
detect the methylation status of exfoliated cell genes in the intestine, help 
screen for colorectal cancer and precancerous lesions risk, and detect bowel 
cancer risk even in the absence of active bleeding lesions, according to BkkGI.

Colorectal cancer is the third most common cancer and the second deadliest 
cancer globally. In 2020, the number of colorectal cancer diagnoses worldwide 
was about 1.9 million.

Older age, a history of bowel disease, a family history of related diseases, 
having type 2 diabetes, being overweight or obese, certain types of diet, 
smoking, and drinking are all risk factors that can lead to colorectal cancer. 
In recent years, the incidence rate of colorectal cancer among young people has 
also been increasing significantly.

As the tumor grows, patients may experience one or multiple symptoms, including 
blood in the stool, abdominal pain , and bloating, among others.

However, colorectal cancer usually does not show any symptoms in the early 
stages, which causes nearly 50% of patients not be detected until they reach 
the third or fourth stage and miss the best time for treatment. If colorectal 
cancer is diagnosed at a early stage, the 5-year relative survival rate of 
patients can be as high as 90%. Conversely, if it is stage IV at the time of 
discovery, the 5-year survival rate will be reduced to only about 10%.

Click here to learn about the new method of early screening for colorectal 
cancer. https://youtu.be/6RVq57jAK8o

A non-invasive, painless, convenient , and the best way to deal with colorectal 
cancer is to actively use COLOTECT and other screening methods to detect and 
treat colorectal cancer as early as possible.

Source: BkkGI